news
AbbVie is to acquire Allergan in a ‘transformative transaction’
AbbVie Inc. and Allergan plc have entered into a definitive transaction agreement under which AbbVie will acquire Allergan.
List view / Grid view
AbbVie
news
Patent litigation for adalimumab resolved in the US
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
news
Upadacitinib receives breakthrough therapy designation for atopic dermatitis
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
article
Guide to Outsourcing
Welcome to European Pharmaceutical Review’s Guide to Outsourcing, the fourth in our series of ‘Guide to…’ supplements. In this edition, five leading companies that provide outsourcing services explain how their portfolio meets current industry needs.
news
NICE recommends access to venclyxto for adult leukaemia
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
news
FDA approves AbbVie’s Mavyret for hepatitis C
The FDA has approved Mavyret to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis...
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
content_hub
AbbVie
19 June 2017 | By
AbbVie may have been founded in 2013, but our roots run deep. In 2013, we became a separate company from Abbott, though we share a common legacy and strong prospects for future success. Our name represents our connection to the past and the future. When we became our own company,…
news
EMA to review Sandoz biosimilars adalimumab and infliximab
Sandoz announced that the EMA has accepted for regulatory review for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab)...
news
AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate
24 April 2017 | By Niamh Marriott, Junior Editor
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype and compensated cirrhosis (Child-Pugh A)...
news
AbbVie receives CHMP positive opinion for Hep C tablet combination
2 March 2017 | By Niamh Marriott, Digital Editor
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…
news
NICE does not recommend AbbVie’s leukaemia drug
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
article
The top 21… wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
news
Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab...
news
AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load...
